Current treatments and challenges for fatty liver disease linked to metabolism

Currently, resmetirom and semaglutide are the only two drugs conditionally approved for patients with fibrosis stages 2-3.

• Metabolic dysfunction-associated steatotic liver disease (MASLD) has a complex pathophysiology involving both metabolic and liver processes.
• A growing number of therapeutic targets are being identified for MASLD, along with a rapidly expanding drug development pipeline.
• Identifying patients who will benefit from new therapies may pose significant clinical challenges.
• A phenotype-based approach that combines metabolic profiles and liver disease stages is recommended for treatment selection.
• Non-invasive tests are crucial for determining treatment eligibility, while metabolic risk profiling and ongoing monitoring could enhance real-world management of MASLD.

Simplified